Steviol, a natural product inhibits proliferation of the gastrointestinal cancer cells intensively
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1470 views | HTML 2005 views | ?
Junming Chen1,2, Yongmei Xia1,2,3, Xiaochen Sui1,2, Qingrui Peng1,2, Tongtong Zhang1,2, Jian Li4 and Jue Zhang4
1State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China
2Key Laboratory of Synthetic and Biological Colloids (Ministry of Education), School of Chemical and Materials Engineering, Jiangnan University, Wuxi, Jiangsu 214122, China
3International Joint Laboratory on Food Safety, Jiangnan University, Wuxi, Jiangsu 214122, China
4Key Laboratory of Nuclear Medicine of Ministry of Health, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu 214063, China
Yongmei Xia, email: [email protected]
Keywords: steviol; steviol glycoside; cancer; gastrointestinal
Received: September 13, 2017 Accepted: March 24, 2018 Published: May 29, 2018
New anticancer agents with lower toxicity have been always urged because of drug resistance associated with overused chemotherapy agents. In this study, steviol, a colonic metabolite of natural sweetener and also a component in leaves of stevia rebaudiana bertoni, was found to possess intensive anticancer activity on the human gastrointestinal cancer cells. Steviol inhibited six human gastrointestinal cancer cells intensively as 5-fluorouracil did at 100 μg/mL. The inhibition mechanism follows mitochondrial apoptotic pathway that was evidenced by increase of Bax/Bcl-2 ratio, activation of p21 and p53; and caspase 3-independent mechanism was also involved. These results are consistent with the miRNA expression analysis. The most regulated miRNAs in the steviol treated gastrointestinal cancer cells were miR-203a-3p (log2 =1.32) and miR-6088 (log2 =-2.54) in HCT-116, miR-1268b (log2 =19.85) and miR-23c (log2 =-2.05) in MKN-45. In view of the metabolic characteristics of steviol and its cytotoxicity on the cancer cells, steviol could be a chemotherapy agent potentially for cancer treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.